- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01328171
FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) (VOLFI)
An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer of RAS wildtype. The patients will be treated in two therapy groups:
Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy with FOLFOXIRI
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Esslingen, Baden-Württemberg, Germany, 73730
- Klinikum Esslingen
-
Heilbronn, Baden-Württemberg, Germany, 74078
- SLK-Kliniken Heilbronn GmbH
-
Lahr, Baden-Württemberg, Germany, 77933
- Ortenau Klinikum
-
Ludwigsburg, Baden-Württemberg, Germany, 71640
- Klinikum Ludwigsburg
-
Mannheim, Baden-Württemberg, Germany, 68135
- Universitätsklinikum Mannheim
-
Mutlangen, Baden-Württemberg, Germany, 73557
- Klinikum Schwäbisch Gmünd
-
Nürtingen, Baden-Württemberg, Germany, 72622
- Kreiskliniken Esslingen gGmbH Klinik Nürtingen
-
Stuttgart, Baden-Württemberg, Germany, 70190
- Schwerpunktpraxis und Tagesklinik Onkologie Hämatologie Gastroenterologie Palliativmedizin Drs. Höring, Respondek, Schwinger, Thunert
-
Ulm, Baden-Württemberg, Germany, 89081
- Universitätsklinikum Ulm Zentrum für Innere Medizin
-
-
Bayern
-
Augsburg, Bayern, Germany, 86156
- Klinikum Augsburg
-
Schweinfurt, Bayern, Germany, 97422
- Leopoldina-Krankenhaus der Stadt Schweinfurth gGmbH
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60590
- Klinikum der J.W. Goethe-Universität Frankfurt
-
Marburg, Hessen, Germany, 35043
- Universitätsklinikum Gießen und Marburg GmbH
-
-
Niedersachsen
-
Georgsmarienhütte, Niedersachsen, Germany, 49124
- Franziskus Hospital Niels-Stensen-Kliniken Klinik für Internistische Onkologie und Hämatologie
-
Osnabrück, Niedersachsen, Germany, 49074
- Marienhospital Osnabrück Niels-Stensen-Kliniken Klinik für Innere Medizin
-
-
Nordrhein-Westfalen
-
Paderborn, Nordrhein-Westfalen, Germany, 33098
- St. Vincenz-Krankenhaus
-
-
Rheinland-Pfalz
-
Trier, Rheinland-Pfalz, Germany, 54290
- Klinikum Mutterhaus der Borromäerinnen gGmbH
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany, 6120
- Universitätsklinikum Halle
-
-
Thüringen
-
Jena, Thüringen, Germany, 7740
- Universitätsklinikum Jena
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Cohort I: Histologically confirmed and definitively inoperable or irresectable metastatic colorectal cancer. Focus on patients with large tumor load at metastatic sites and/or symptomatic metastatic disease
- Cohort II: Chance of secondary resection with curative intent defined and reviewed by expert panel
- Adult patients (≥ 18 years of age)
RAS wild-type tested in
- KRAS exon 2 (codons 12/13)
- KRAS exon 3 (codons 59/61)
- KRAS exon 4 (codons 117/146)
- NRAS exon 2 (codons 12/13)
- NRAS exon 3 (codons 59/61)
- NRAS exon 4 (codons 117/146) assessed by an institution participating in and certified by the specific working group of the Deutsche Gesellschaft für Pathologie)
- At least one measurable lesion according to RECIST measured within 3 weeks prior to registration
- No previous chemotherapy for metastatic disease (adjuvant chemotherapy for non-metastatic disease is allowed if terminated more than 6 months ago)
- Performance status ECOG 0-1
- Male and female subjects > 18 years of age
- Adequate haematological, hepatic, renal and metabolic function parameters:
Leukocytes > 3000/mm³, ANC ≥ 1500/mm3, platelets ≥ 100,000/mm3, Hb > 9g/dl (may be transfused or treated with erythropoietin to maintain or exceed this level)Creatinine clearance ≥ 50 ml/min or serum creatinine ≤ 1.5 x upper limit of normal Bilirubin ≤ 1.5 x upper limit of normal, GOT-GPT ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver metastases, AP ≤ 5 x upper limit of normal Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal (may be substituted to maintain or exceed this level)
- Negative pregnancy test and willingness to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment (adequate: oral contraceptives, intrauterine device or barrier method in conjunction with spermicidal jelly).
- Before subject registration, written informed consent must be given according to ICH-GCP, and national/local regulations.
Exclusion Criteria:
- Past or current history of malignancies except for the indication under this study and curatively treated:
- Basal and squamous cell carcinoma of the skin
- In-situ carcinoma of the cervix
- Other malignant disease without recurrence after at least 5 years of follow-up
- Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 6 months before enrolment.
- Clinically relevant interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
- History of evidence upon physical examination of CNS disease unless adequately treated (e.g. primary brain tumour, seizure not controlled with standard medical therapy, brain metastases or history of stroke).
- Pre-existing neuropathy > grade 1 (NCI CTCAE), except for loss of tendon reflex
- Allogeneic transplantation requiring immunosuppressive therapy.
- Severe non-healing wounds, ulcers or bone fractions.
- Evidence of bleeding diathesis or coagulopathy.
- Patients not receiving therapeutic anticoagulation must have an INR < 1,5 ULN and aPTT < 1,5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or aPTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least two weeks at the time of randomisation.
- Concomitant therapy with certain anti-viral medicines (sorivudine and brivudine or analogue compounds).
- Major surgical procedure, open biopsy, nor significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study except for surgery for colorectal cancer with curative intent and central venous line placement for chemotherapy administration.
- Pregnancy or breastfeeding women.
- Subjects with known allergy to the study drugs or to any of its excipients.
- Known DPD deficiency.
- Current or recent (within the 28 days prior to starting study treatment) treatment of another investigational drug or participation in another investigational study.
- Known grade III/IV allergic reaction against monoclonal antibodies.
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A (FOLFOXIRI + Panitumumab)
FOLFOXIRI + Panitumumab
|
irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont.
inf.
+ panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Other Names:
|
Active Comparator: B (FOLFOXIRI)
FOLFOXIRI
|
irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont.
inf.
all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall response rate
Time Frame: up to about 6 month
|
RECIST
|
up to about 6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall response rate in each cohort
Time Frame: up to about 6 month
|
RECIST
|
up to about 6 month
|
secondary resection rate with curative intent for patients cohort I
Time Frame: up to about 6 month
|
up to about 6 month
|
|
pathological response in liver surgery specimen
Time Frame: up to about 6 month
|
metrics: Pathological complete response (pCR): no residual cancer cells;major response (pPR): 1% to 49% residual cancer cells remaining; minor response (pMR): 50% to 99% residual cancer cells remaining; no response (pNR): 100% residual cancer cells remaining
|
up to about 6 month
|
disease control rate
Time Frame: up to about 6 month
|
CR + PR + SD rate according to RECIST
|
up to about 6 month
|
progression free survival
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years
|
|
duration of response
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years
|
analyzed for responders only
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years
|
time to response
Time Frame: up to about 6 month
|
up to about 6 month
|
|
overall survival
Time Frame: From date of randomization until the date of death from any cause assessed up to 4 years
|
From date of randomization until the date of death from any cause assessed up to 4 years
|
|
time to recurrence (cohort II in case of secondary resection)
Time Frame: up to 4 years
|
up to 4 years
|
|
toxicity and feasibility
Time Frame: up to about 6 month
|
number of patients with adverse events and severity according to NCI CTC 3.0
|
up to about 6 month
|
liver toxicity for resected patients (central histological review); biopsies should be obtained for all patients pre-treatment
Time Frame: up to 1 year
|
histological findings according to CASH/SOS scores
|
up to 1 year
|
QL (QLQ C30)
Time Frame: Pre-treatment, before start of every 3rd cycle and at the end of treatment
|
scores according to EORTC QLQ-C30 scoring manual (Quality of life)
|
Pre-treatment, before start of every 3rd cycle and at the end of treatment
|
translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes
Time Frame: up to 4 years
|
Determination of EGFR mutations (exons 18, 19, 20, 21) in tumor tissue; determination of PIK3CA mutations (exon 9, 20) in tumor tissue; determination of EGFR, ERCC1, TS, MTHFR, OPRT, DHFR and CDKN polymorphism from normal and tumor tissue; determination of ERCC1, PTEN and TS protein expression in tumor tissue; epigenetic candidates; further exploratory studies such as miRNA analysis as approved by the AIO review board
|
up to 4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Geißler, MD, PhD, Department of Oncology and Gastroenterology, Academic Teaching Hospital Esslingen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Hematinics
- Oxaliplatin
- Irinotecan
- Folic Acid
- Vitamin B Complex
- Panitumumab
Other Study ID Numbers
- AIO KRK 0109
- 2009-017731-17 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy
Clinical Trials on FOLFOXIRI + Panitumumab
-
Gruppo Oncologico del Nord-OvestCompletedMetastatic Colo-rectal CancerItaly
-
Hospital Universitari de BellvitgeInstituto de Salud Carlos IIITerminatedResection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (CCRe-IV)Colonic Cancer | Unresectable Metastasis Originating in Colonic CancerSpain
-
Azienda Ospedaliero, Universitaria PisanaCompletedPancreatic Carcinoma Stage IIIItaly
-
Fujian Cancer HospitalNot yet recruitingAdvanced Colorectal Cancer
-
University of Alabama at BirminghamRecruiting
-
AIPING ZHOUCompletedLocally Advanced Rectal CancerChina
-
Spanish Cooperative Group for the Treatment of...AmgenCompleted
-
Radboud University Medical CenterTerminatedIrresectable Squamous Cell or Adenocarcinoma of the OesophagusNetherlands
-
TakedaCompleted
-
WiSP Wissenschaftlicher Service Pharma GmbHGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHTerminatedUrinary Bladder CancerGermany